Blood Reviews
Volume 22, Issue 6 , Pages 311-320 , November 2008

Induction therapy for elderly patients with acute myeloid leukemia

References 

  1. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site; 2007.
  2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908–1915
  3. National Comprehensive Cancer Network Guidelines. Acute myeloid leukemia, version2.2007.
  4. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485
  5. Pretbet T, Bernard F, Etienne A, et al. High relapse rate of acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy. In: American society of hematology annual meeting; 2007 [abstract 4365].
  6. Leith C, Kopecky K, Godwin J, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy—A Southwest Oncology Group study. Blood. 1997;89:3323–3329
  7. Dombert H, Malfuson J-V, Etienne A, et al. Decision criteria for the futility of intensive chemotherapy in older patients with acute myeloid leukemia. In: American society of hematology annual meeting; 2007 [abstract 2861].
  8. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597–1603
  9. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European organization for the research and treatment of cancer leukemia group. J Clin Oncol. 1989;7:1268–1274
  10. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8:272–279
  11. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124
  12. Becker C, Krahl R, Al Ali HK, et al. High CR-rate after intensive chemotherapy but disappointing results after palliative treatment in patients with acute myeloid leukemia above the age of 60 years: an analysis of the AML97#38 study of the East German Hematology and Oncology study group (OSHO). In: American society of hematology annual meeting; 2007 [abstract 1854].
  13. Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106:1090–1098
  14. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized acute leukemia French association (ALFA) 9803 trial. Blood. 2007;109:5129–5135
  15. Jehn U, Suciu S, Thomas X, et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia. 2006;20:1723–1730
  16. Knapper S, Burnett A, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262–3270
  17. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224–1232
  18. Cripe L, Li X, Litzow M, et al. A randomized placebo-controlled, double-blind trial of the MDR modulator zosuquidar during conventional induction and post-remission therapy for patients 60 years of age with newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2006;108:129;abstr 423
  19. Mylotarg (Gemtuzumab ozogamicin) package insert.
  20. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343–4349
  21. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004;89:950–956
  22. Harousseau J-L, Recher CFR, Vey N, et al. Gemtuzumab–ozogamicin (GO) plus idarubicin (I) and cytarabine (C) as induction treatment for elderly patients with poor-risk cytogenetics acute myeloid leukemia. In: American society of hematology annual meeting; 2007 [abstract 1839].
  23. Blum W, Marcucci G. Targeting epigenetic changes in acute myeloid leukemia. Clin Adv Hematol Oncol. 2005;3:855–865
  24. Lubbert M, Ruter B, Schmid M, et al. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: first results of a mutlicenter phase II study. In: American society of hematology annual meeting; 2005 [abstract 1852].
  25. Cashen A, Schiller GJ, Larsen JS, et al. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). In: American society of hematology annual meeting; 2005 [abstract 1984].
  26. Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitadine. Cancer. 2006;107:1839–1843
  27. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202
  28. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004;112:171–178
  29. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–1066
  30. Kalff A, Shortt J, Farr J, et al. Laboratory tumor lysis complicating LBH589 therapy in a patient with acute myeloid leukemia. In: American society of hematology annual meeting; 2006 [abstract 4554].
  31. Spencer A, Prince M, DeAngelo DJ, et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. In: American society of hematology annual meeting; 2007 [abstract 907].
  32. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884–3891
  33. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–2308
  34. Ravandi F, Faderl S, Thomas D, et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. In: American society of hematology annual meeting; 2007 [abstract 897].
  35. Burnett AK, Baccarani M, Johnson P, et al. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. In: American society of hematology annual meeting; 2006 [abstract 425].
  36. Faderl S, Ravandi F, Ferrajoli A, et al. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients >60 years with newly diagnosed acute myeloid leukemia. In: American society of hematology annual meeting; 2006 [abstract 2804].
  37. Foran J, The A, Dixon P, et al. Phase I study of clofarabine with standard-dose infusional cytarabine (Ara-C) as intensive induction therapy for newly-diagnosed de novo acute myeloid leukemia in older adults age >60 years. In: American society of hematology annual meeting; 2007 [abstract 1831].
  38. Agura E, Berryman RB, Brougher L, et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high-risk of anthracycline toxicity. In: American society of hematology annual meeting; 2006 [abstract 1951].
  39. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007;25:25–31
  40. Schiller GJ, DeAngelo DJ, Pigneux A, et al. Phase II study of VNP40101M in elderly patients with de novo poor risk acute myelogenous leukemia. In: American society of hematology annual meeting; 2007 [abstract 917].
  41. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999;17:241–258
  42. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-correlative trial. Blood. 2001;97:3361–3369
  43. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387–1394
  44. Harousseau J-L, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. In: American society of hematology annual meeting; 2007 [abstract 439].
  45. Brandwein JM, Leber BF, Howson-Jan K, et al. A phase I study of tipifarnib combined with conventional induction and consolidation therapy in previously untreated patients with acute myeloid leukemia age 60 and over. In: American society of hematology annual meeting; 2007 [abstract 899].
  46. Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol. 2007;5:1–9
  47. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New Engl J Med. 2006;355:1456–1465
  48. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karotypes other than deletion 5q. Blood. 2008;111:86–93
  49. Fehniger TA, Nelson A, Trinkaus K, et al. Phase II study of high dose lenalidomide as initial treatment for older acute myeloid leukemia patients: early results show a significant reduction of bone marrow blasts after 14 days of therapy. In: American society of hematology annual meeting; 2007 [abstract 916].
  50. Personal communication with Ravi Vij, MD on 3/1/08.
  51. Borthakur G, Garcia-Manero G, Faderl S, et al. Lenalidomide in high-risk myelodysplastic syndrome and acute myelogenous leukemia associated with chromosome 5 abnormalities. In: American society of hematology annual meeting; 2007 [abstract 1459].
  52. Delmonte J, Kantarjian H, Andreeff M, et al. Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. In: American society of hematology annual meeting; 2007 [abstract 893].
  53. Boehrer S, Ades L, Braun T, et al. Erlotinib exhibits anti-neoplastic off-target effects in AML and MDS: a preclinical study. Blood [prepublished online November 21, 2007].
  54. Chan G, Pilichowska . Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non-small cell lung cancer. Blood. 2007;110:1079–1080
  55. Stegmaier K, Corsello SM, Ross KN, et al. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005;106:2841–2848

PII: S0268-960X(08)00039-8

doi: 10.1016/j.blre.2008.04.004

Blood Reviews
Volume 22, Issue 6 , Pages 311-320 , November 2008

Article Tools